Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Feliciano JL, McLoone D, Xu Y, Quek RGW, Kuznik A, Pouliot JF, Gullo G, Rietschel P, Guyot P, Konidaris G, Chan K, Keeping S, Wilson FR, Freemantle N. Feliciano JL, et al. Among authors: freemantle n. Front Oncol. 2023 Apr 4;12:1081729. doi: 10.3389/fonc.2022.1081729. eCollection 2022. Front Oncol. 2023. PMID: 37082098 Free PMC article.
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'.
Bastian M, Freemantle N, Rossi AB, Shumel B, Le Bagousse GB, Wang Z, Xu Y, Guyot P. Bastian M, et al. Among authors: freemantle n. Dermatol Ther (Heidelb). 2024 Mar;14(3):819-821. doi: 10.1007/s13555-024-01106-2. Epub 2024 Feb 16. Dermatol Ther (Heidelb). 2024. PMID: 38366176 Free PMC article. No abstract available.
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
Haluzík M, Seufert J, Guja C, Bonnemaire M, Bigot G, Tournay M, Kis JT, Freemantle N. Haluzík M, et al. Among authors: freemantle n. Diabetes Ther. 2023 Apr;14(4):639-652. doi: 10.1007/s13300-023-01375-8. Epub 2023 Feb 14. Diabetes Ther. 2023. PMID: 36787044 Free PMC article.
Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database.
Müller-Wieland D, Freemantle N, Bonadonna RC, Mauquoi C, Bigot G, Bonnemaire M, Gourdy P, Mauricio D. Müller-Wieland D, et al. Among authors: freemantle n. Diabetes Ther. 2023 Feb;14(2):401-413. doi: 10.1007/s13300-022-01356-3. Epub 2023 Jan 4. Diabetes Ther. 2023. PMID: 36596946 Free PMC article.
Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England's National Institute of Health and Care Excellence.
Ferizovic N, Plackett R, Clarke CS, Hunter R, Freemantle N. Ferizovic N, et al. Among authors: freemantle n. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan 19:1-17. doi: 10.1080/14737167.2025.2455405. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2025. PMID: 39817536
596 results